KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Net Cash Flow: 2011-2024

Historic Net Cash Flow for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $1.3 million.

  • Travere Therapeutics' Net Cash Flow rose 870.50% to $35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.8 million, marking a year-over-year increase of 169.99%. This contributed to the annual value of $1.3 million for FY2024, which is 100.50% up from last year.
  • Travere Therapeutics' Net Cash Flow amounted to $1.3 million in FY2024, which was up 100.50% from -$256.8 million recorded in FY2023.
  • Travere Therapeutics' Net Cash Flow's 5-year high stood at $23.9 million during FY2021, with a 5-year trough of -$256.8 million in FY2023.
  • In the last 3 years, Travere Therapeutics' Net Cash Flow had a median value of -$173.3 million in 2022 and averaged -$143.0 million.
  • Per our database at Business Quant, Travere Therapeutics' Net Cash Flow spiked by 158.48% in 2020 and then plummeted by 824.51% in 2022.
  • Over the past 5 years, Travere Therapeutics' Net Cash Flow (Yearly) stood at $23.6 million in 2020, then rose by 1.20% to $23.9 million in 2021, then plummeted by 824.51% to -$173.3 million in 2022, then tumbled by 48.17% to -$256.8 million in 2023, then soared by 100.50% to $1.3 million in 2024.